

Michael J Mullan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3101006/publications.pdf>

Version: 2024-02-01

169
papers

9,709
citations

39113

52
h-index

49824

91
g-index

170
all docs

170
docs citations

170
times ranked

11830
citing authors

#	ARTICLE	IF	CITATIONS
1	Sex-specific differences in plasma lipid profiles are associated with Gulf War Illness. <i>Journal of Translational Medicine</i> , 2022, 20, 73.	1.8	5
2	Exogenous lipase administration alters gut microbiota composition and ameliorates Alzheimer's disease-like pathology in APP/PS1 mice. <i>Scientific Reports</i> , 2022, 12, 4797.	1.6	6
3	Adaptive Immune Responses Associated with the Central Nervous System Pathology of Gulf War Illness. <i>Neuroscience Insights</i> , 2021, 16, 263310552110184.	0.9	6
4	Mural cell dysfunction leads to altered cerebrovascular tau uptake following repetitive head trauma. <i>Neurobiology of Disease</i> , 2021, 150, 105237.	2.1	12
5	Novel, natural allosteric inhibitors and enhancers of <i>Candida rugosa</i> lipase activity. <i>Bioorganic Chemistry</i> , 2021, 109, 104732.	2.0	3
6	MMP9 modulation improves specific neurobehavioral deficits in a mouse model of Alzheimer's disease. <i>BMC Neuroscience</i> , 2021, 22, 39.	0.8	25
7	Molecular Pathobiology of the Cerebrovasculature in Aging and in Alzheimer's Disease Cases With Cerebral Amyloid Angiopathy. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 658605.	1.7	11
8	Influence of traumatic brain injury on extracellular tau elimination at the blood-brain barrier. <i>Fluids and Barriers of the CNS</i> , 2021, 18, 48.	2.4	8
9	<i>Candida rugosa</i> lipase alters the gastrointestinal environment in wild-type mice. <i>Biomedicine and Pharmacotherapy</i> , 2020, 130, 110579.	2.5	3
10	The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial. <i>Frontiers in Neurology</i> , 2020, 11, 149.	1.1	14
11	Apolipoprotein E isoforms differentially regulate matrix metalloproteinase 9 function in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 95, 56-68.	1.5	13
12	Targeting sirtuin activity with nicotinamide riboside reduces neuroinflammation in a GWI mouse model. <i>NeuroToxicology</i> , 2020, 79, 84-94.	1.4	23
13	Unbiased Proteomic Approach Identifies Pathobiological Profiles in the Brains of Preclinical Models of Repetitive Mild Traumatic Brain Injury, Tauopathy, and Amyloidosis. <i>ASN Neuro</i> , 2020, 12, 175909142091476.	1.5	7
14	Chronic White Matter Degeneration, but No Tau Pathology at One-Year Post-Repetitive Mild Traumatic Brain Injury in a Tau Transgenic Model. <i>Journal of Neurotrauma</i> , 2019, 36, 576-588.	1.7	40
15	A permethrin metabolite is associated with adaptive immune responses in Gulf War Illness. <i>Brain, Behavior, and Immunity</i> , 2019, 81, 545-559.	2.0	31
16	Distinct Signaling Pathways Regulate TREM2 Phagocytic and NF- κ B Antagonistic Activities. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 457.	1.8	61
17	A fast, miniaturised <i>in-vitro</i> assay developed for quantification of lipase enzyme activity. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2019, 34, 1474-1480.	2.5	5
18	APOE Genotype Specific Effects on the Early Neurodegenerative Sequelae Following Chronic Repeated Mild Traumatic Brain Injury. <i>Neuroscience</i> , 2019, 404, 297-313.	1.1	25

#	ARTICLE	IF	CITATIONS
19	Influence of Matrix Metallopeptidase 9 on Beta-Amyloid Elimination Across the Blood-Brain Barrier. <i>Molecular Neurobiology</i> , 2019, 56, 8296-8305.	1.9	19
20	Converging and Differential Brain Phospholipid Dysregulation in the Pathogenesis of Repetitive Mild Traumatic Brain Injury and Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2019, 13, 103.	1.4	33
21	Impact of Repetitive Mild Traumatic Brain Injury on Behavioral and Hippocampal Deficits in a Mouse Model of Chronic Stress. <i>Journal of Neurotrauma</i> , 2019, 36, 2590-2607.	1.7	16
22	Lifelong behavioral and neuropathological consequences of repetitive mild traumatic brain injury. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 64-80.	1.7	110
23	Unbiased Proteomic Approach Identifies Unique and Coincidental Plasma Biomarkers in Repetitive mTBI and AD Pathogenesis. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 405.	1.7	9
24	Subchronic Pathobiological Response Following Chronic Repetitive Mild Traumatic Brain Injury in an Aged Preclinical Model of Amyloid Pathogenesis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 1144-1162.	0.9	2
25	Disruption in Brain Phospholipid Content in a Humanized Tau Transgenic Model Following Repetitive Mild Traumatic Brain Injury. <i>Frontiers in Neuroscience</i> , 2018, 12, 893.	1.4	18
26	Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. <i>PLoS Medicine</i> , 2018, 15, e1002660.	3.9	131
27	Oleoylethanolamide treatment reduces neurobehavioral deficits and brain pathology in a mouse model of Gulf War Illness. <i>Scientific Reports</i> , 2018, 8, 12921.	1.6	36
28	Impact of age on acute post-TBI neuropathology in mice expressing humanized tau: a Chronic Effects of Neurotrauma Consortium study. <i>Brain Injury</i> , 2018, 32, 1285-1294.	0.6	25
29	Acute or Delayed Treatment with Anatabine Improves Spatial Memory and Reduces Pathological Sequelae at Late Time-Points after Repetitive Mild Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2017, 34, 1676-1691.	1.7	29
30	Mild TBI Results in a Long-Term Decrease in Circulating Phospholipids in a Mouse Model of Injury. <i>NeuroMolecular Medicine</i> , 2017, 19, 122-135.	1.8	46
31	Negative Impact of Female Sex on Outcomes from Repetitive Mild Traumatic Brain Injury in hTau Mice Is Age Dependent: A Chronic Effects of Neurotrauma Consortium Study. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 416.	1.7	26
32	Phospholipid profiling of plasma from GW veterans and rodent models to identify potential biomarkers of Gulf War Illness. <i>PLoS ONE</i> , 2017, 12, e0176634.	1.1	39
33	APOE ϵ 4 specific imbalance of arachidonic acid and docosahexaenoic acid in serum phospholipids identifies individuals with preclinical Mild Cognitive Impairment/Alzheimer's Disease. <i>Aging</i> , 2017, 9, 964-985.	1.4	58
34	Sub-Chronic Neuropathological and Biochemical Changes in Mouse Visual System after Repetitive Mild Traumatic Brain Injury. <i>PLoS ONE</i> , 2016, 11, e0153608.	1.1	40
35	Translational potential of long-term decreases in mitochondrial lipids in a mouse model of Gulf War Illness. <i>Toxicology</i> , 2016, 372, 22-33.	2.0	50
36	European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease—the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow. <i>BMJ Open</i> , 2016, 6, e011584.	0.8	21

#	ARTICLE	IF	CITATIONS
37	Chronic Repetitive Mild Traumatic Brain Injury Results in Reduced Cerebral Blood Flow, Axonal Injury, Gliosis, and Increased T-Tau and Tau Oligomers. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 636-655.	0.9	104
38	Plasma Lipidomic Profiling in a Military Population of Mild Traumatic Brain Injury and Post-Traumatic Stress Disorder with Apolipoprotein E ε4-Dependent Effect. <i>Journal of Neurotrauma</i> , 2016, 33, 1331-1348.	1.7	43
39	Gulf War Agent Exposure Causes Impairment of Long-Term Memory Formation and Neuropathological Changes in a Mouse Model of Gulf War Illness. <i>PLoS ONE</i> , 2015, 10, e0119579.	1.1	68
40	Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD. <i>PLoS ONE</i> , 2015, 10, e0128224.	1.1	26
41	Ultrastructural Changes in the White and Gray Matter of Mice at Chronic Time Points After Repeated Concussive Head Injury. <i>Journal of Neuropathology and Experimental Neurology</i> , 2015, 74, 1012-1035.	0.9	54
42	Neurobehavioral, neuropathological and biochemical profiles in a novel mouse model of co-morbid post-traumatic stress disorder and mild traumatic brain injury. <i>Frontiers in Behavioral Neuroscience</i> , 2014, 8, 213.	1.0	46
43	Apolipoprotein E Isoform-Specific Effects on Lipoprotein Receptor Processing. <i>NeuroMolecular Medicine</i> , 2014, 16, 686-696.	1.8	41
44	The Spleen Tyrosine Kinase (Syk) Regulates Alzheimer Amyloid-β ₂ Production and Tau Hyperphosphorylation. <i>Journal of Biological Chemistry</i> , 2014, 289, 33927-33944.	1.6	84
45	Lipidomic analyses identify injury-specific phospholipid changes 3 mo after traumatic brain injury. <i>FASEB Journal</i> , 2014, 28, 5311-5321.	0.2	85
46	Exposure to an organophosphate pesticide, individually or in combination with other G _{ulf} War agents, impairs synaptic integrity and neuronal differentiation, and is accompanied by subtle microvascular injury in a mouse model of G _{ulf} War agent exposure. <i>Neuropathology</i> , 2014, 34, 109-127.	0.7	64
47	Chronic neuropathological and neurobehavioral changes in a repetitive mild traumatic brain injury model. <i>Annals of Neurology</i> , 2014, 75, 241-254.	2.8	298
48	Repetitive Mild Traumatic Brain Injury Causes Optic Nerve and Retinal Damage in a Mouse Model. <i>Journal of Neuropathology and Experimental Neurology</i> , 2014, 73, 345-361.	0.9	76
49	NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease. <i>BMJ Open</i> , 2014, 4, e006364.	0.8	47
50	Role of the cannabinoid system in the transit of beta-amyloid across the blood-brain barrier. <i>Molecular and Cellular Neurosciences</i> , 2013, 56, 255-262.	1.0	39
51	Effect of Venlafaxine and Desvenlafaxine on Drug Efflux Protein Expression and Biodistribution In Vivo. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 3838-3843.	1.6	21
52	Stimulation of the Retinoid X Receptor Facilitates Beta-Amyloid Clearance Across the Blood-Brain Barrier. <i>Journal of Molecular Neuroscience</i> , 2013, 49, 270-276.	1.1	38
53	Chronic elevation of phosphocholine containing lipids in mice exposed to Gulf War agents pyridostigmine bromide and permethrin. <i>Neurotoxicology and Teratology</i> , 2013, 40, 74-84.	1.2	62
54	A Multifaceted Role for apoE in the Clearance of Beta-Amyloid across the Blood-Brain Barrier. <i>Neurodegenerative Diseases</i> , 2013, 11, 13-21.	0.8	42

#	ARTICLE	IF	CITATIONS
55	Anti-inflammatory activity of anatabine via inhibition of STAT3 phosphorylation. <i>European Journal of Pharmacology</i> , 2013, 698, 145-153.	1.7	45
56	Amelioration of Experimental Autoimmune Encephalomyelitis by Anatabine. <i>PLoS ONE</i> , 2013, 8, e55392.	1.1	36
57	Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients—an open-label trial. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 415-422.	1.3	33
58	Identification of Plasma Biomarkers of TBI Outcome Using Proteomic Approaches in an APOE Mouse Model. <i>Journal of Neurotrauma</i> , 2012, 29, 246-260.	1.7	31
59	Repetitive Mild Traumatic Brain Injury in a Mouse Model Produces Learning and Memory Deficits Accompanied by Histological Changes. <i>Journal of Neurotrauma</i> , 2012, 29, 2761-2773.	1.7	269
60	Lipidomic Profiling of Phosphocholine Containing Brain Lipids in Mice with Sensorimotor Deficits and Anxiety-Like Features After Exposure to Gulf War Agents. <i>NeuroMolecular Medicine</i> , 2012, 14, 349-361.	1.8	79
61	Plasma microRNA biomarkers for detection of mild cognitive impairment. <i>Aging</i> , 2012, 4, 590-605.	1.4	163
62	Depletion of CXCR2 inhibits β -secretase activity and amyloid- β production in a murine model of Alzheimer's disease. <i>Cytokine</i> , 2011, 53, 163-169.	1.4	43
63	Extended results of the Alzheimer's disease anti-inflammatory prevention trial. <i>Alzheimer's and Dementia</i> , 2011, 7, 402-411.	0.4	290
64	Feasibility of Predicting MCI/AD Using Neuropsychological Tests and Serum β -Amyloid. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-7.	1.1	5
65	Selective Antihypertensive Dihydropyridines Lower $A\beta$ Accumulation by Targeting both the Production and the Clearance of $A\beta$ across the Blood-Brain Barrier. <i>Molecular Medicine</i> , 2011, 17, 149-162.	1.9	104
66	Epitope-Dependent Effects of Beta-Amyloid Antibodies on Beta-Amyloid Clearance in an In Vitro Model of the Blood-Brain Barrier. <i>Microcirculation</i> , 2011, 18, 373-379.	1.0	9
67	Selective dihydropyridine compounds facilitate the clearance of β -amyloid across the blood-brain barrier. <i>European Journal of Pharmacology</i> , 2011, 659, 124-129.	1.7	61
68	Anatabine lowers Alzheimer's $A\beta$ production in vitro and in vivo. <i>European Journal of Pharmacology</i> , 2011, 670, 384-391.	1.7	51
69	Proteomic CNS Profile of Delayed Cognitive Impairment in Mice Exposed to Gulf War Agents. <i>NeuroMolecular Medicine</i> , 2011, 13, 275-288.	1.8	69
70	Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine. <i>Biopharmaceutics and Drug Disposition</i> , 2011, 32, 233-244.	1.1	43
71	Flavonoids lower Alzheimer's $A\beta$ production via an NF κ B dependent mechanism. <i>Bioinformatics</i> , 2011, 6, 229-236.	0.2	39
72	Characterization and use of human brain microvascular endothelial cells to examine β -amyloid exchange in the blood-brain barrier. <i>Cytotechnology</i> , 2010, 62, 519-529.	0.7	30

#	ARTICLE	IF	CITATIONS
73	Anti-Tumoral Activity of a Short Decapeptide Fragment of the Alzheimer's A β Peptide. <i>International Journal of Peptide Research and Therapeutics</i> , 2010, 16, 23-30.	0.9	5
74	Alzheimer's A β amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFR2. <i>Journal of Neurochemistry</i> , 2010, 112, 66-76.	2.1	84
75	Impaired Orthotopic Glioma Growth and Vascularization in Transgenic Mouse Models of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2010, 30, 11251-11258.	1.7	25
76	Reduction of A β -amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2010, 7, 17.	3.1	148
77	A 3D-QSAR model based screen for dihydropyridine-like compound library to identify inhibitors of amyloid beta (A β) production. <i>Bioinformatics</i> , 2010, 5, 122-127.	0.2	6
78	High Serum A β and Vascular Risk Factors in First-Degree Relatives of Alzheimer's Disease Patients. <i>Molecular Medicine</i> , 2009, 15, 95-100.	1.9	16
79	Serum A β Levels as Predictors of Conversion to Mild Cognitive Impairment/Alzheimer Disease in an ADAPT Subcohort. <i>Molecular Medicine</i> , 2009, 15, 432-437.	1.9	19
80	Serum A β -Amyloid Correlates with Neuropsychological Impairment. <i>Aging, Neuropsychology, and Cognition</i> , 2009, 16, 203-218.	0.7	17
81	CD40/CD40L interaction induces A β production and increases β -secretase activity independently of tumor necrosis factor receptor associated factor (TRAF) signaling. <i>Experimental Cell Research</i> , 2009, 315, 2265-2274.	1.2	8
82	Cross validation of the Montreal Cognitive Assessment in community dwelling older adults residing in the Southeastern US. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 197-201.	1.3	419
83	Structural optimization of a CXCR2-directed antagonist that indirectly inhibits β -secretase and reduces A β . <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 8102-8112.	1.4	16
84	A Novel Physico-Chemical Property Based Model for Studying the Effects of Mutation on the Aggregation of Peptides. <i>Protein and Peptide Letters</i> , 2009, 16, 991-998.	0.4	0
85	Proteomic Analysis of Human Neuronal Cells Treated with the Gulf War Agent Pyridostigmine Bromide. <i>Journal of Proteomics and Bioinformatics</i> , 2009, 02, 439-444.	0.4	2
86	CD40 ligation mediates plaque-associated tau phosphorylation in A β -amyloid overproducing mice. <i>Brain Research</i> , 2008, 1231, 132-142.	1.1	10
87	The granulocyte macrophage colony stimulating factor (GM-CSF) regulates amyloid A β production. <i>Cytokine</i> , 2008, 42, 336-344.	1.4	16
88	Diagnostic utility of APOE, soluble CD40, CD40L, and A β 1-40 levels in plasma in Alzheimer's disease. <i>Cytokine</i> , 2008, 44, 283-287.	1.4	37
89	Novel Role of CXCR2 in Regulation of β -Secretase Activity. <i>ACS Chemical Biology</i> , 2008, 3, 777-789.	1.6	40
90	Cognitive Function Over Time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). <i>Archives of Neurology</i> , 2008, 65, 896.	4.9	354

#	ARTICLE	IF	CITATIONS
91	Potent anti-angiogenic motifs within the Alzheimer β -amyloid peptide. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2008, 15, 5-19.	1.4	15
92	Neuropsychological Comparison of Alzheimer's Disease and Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 120-125.	0.7	42
93	Cocaine-induced oxidative stress precedes cell death in human neuronal progenitor cells. <i>Neurochemistry International</i> , 2007, 50, 69-73.	1.9	69
94	Inhibition of $A\beta$ production by NF- κ B inhibitors. <i>Neuroscience Letters</i> , 2007, 415, 11-16.	1.0	79
95	The influence of diagnosis, intra- and inter-person variability on serum and plasma $A\beta$ levels. <i>Neuroscience Letters</i> , 2007, 428, 53-58.	1.0	34
96	CD40 promotion of amyloid beta production occurs via the NF- κ B pathway. <i>European Journal of Neuroscience</i> , 2007, 25, 1685-1695.	1.2	19
97	Genomic analysis of response to traumatic brain injury in a mouse model of Alzheimer's disease (APPsw). <i>Brain Research</i> , 2007, 1185, 45-58.	1.1	18
98	CD40 deficiency mitigates Alzheimer's disease pathology in transgenic mouse models. <i>Journal of Neuroinflammation</i> , 2006, 3, 3.	3.1	26
99	The cyclooxygenase 2 -765 C promoter allele is a protective factor for Alzheimer's disease. <i>Neuroscience Letters</i> , 2006, 395, 240-243.	1.0	38
100	Cocaine induced inflammatory response in human neuronal progenitor cells. <i>Journal of Neurochemistry</i> , 2006, 97, 662-674.	2.1	16
101	Beneficial Effect of Cholinesterase Inhibitor Medications on Recognition Memory Performance in Mild to Moderate Alzheimer's Disease: Preliminary Findings. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2006, 19, 13-15.	1.2	10
102	Inhibition of angiogenesis and tumor growth by β and γ -secretase inhibitors. <i>European Journal of Pharmacology</i> , 2005, 514, 1-15.	1.7	86
103	Model of Alzheimer's disease amyloid- β peptide based on a RNA binding protein. <i>Biochemical and Biophysical Research Communications</i> , 2005, 332, 585-592.	1.0	17
104	Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2005, 2, 9.	3.1	262
105	Nilvadipine antagonizes both $A\beta$ vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice. <i>Brain Research</i> , 2004, 999, 53-61.	1.1	77
106	Behavioral effects of CD40/CD40L pathway disruption in aged PSAPP mice. <i>Brain Research</i> , 2004, 1015, 161-168.	1.1	37
107	Inhibition of Angiogenesis by $A\beta$ Peptides. <i>Angiogenesis</i> , 2004, 7, 75-85.	3.7	119
108	No association between subjective memory complaints and apolipoprotein E genotype in cognitively intact elderly. <i>International Journal of Geriatric Psychiatry</i> , 2004, 19, 1131-1139.	1.3	31

#	ARTICLE	IF	CITATIONS
109	Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis. <i>Neuroscience Letters</i> , 2004, 366, 80-85.	1.0	121
110	Blocking Angiogenesis and Tumorigenesis with GFA-116, a Synthetic Molecule that Inhibits Binding of Vascular Endothelial Growth Factor to its Receptor. <i>Cancer Research</i> , 2004, 64, 3586-3592.	0.4	65
111	Apolipoprotein E polymorphism and age of onset for Alzheimer's disease in a bi-ethnic sample. <i>International Psychogeriatrics</i> , 2004, 16, 317-326.	0.6	14
112	Increased TNF α production and Cox-2 activity in organotypic brain slice cultures from APPsw transgenic mice. <i>Neuroscience Letters</i> , 2003, 353, 66-68.	1.0	22
113	Vasoactive effects of A β in isolated human cerebrovessels and in a transgenic mouse model of Alzheimer's disease: Role of inflammation. <i>Neurological Research</i> , 2003, 25, 642-651.	0.6	112
114	Differences in Executive Functioning Between Alzheimer's Disease and Subcortical Ischemic Vascular Dementia. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2002, 24, 745-754.	0.8	53
115	Memory Patterns and Executive Functioning in Mild Cognitive Impairment and Alzheimer's Disease. <i>Aging, Neuropsychology, and Cognition</i> , 2002, 9, 288-297.	0.7	58
116	Apolipoprotein E Polymorphism and Cognitive Impairment in A Bi-Ethnic Community-Dwelling Elderly Sample. <i>Alzheimer Disease and Associated Disorders</i> , 2002, 16, 8-14.	0.6	13
117	Apolipoprotein E Genotype and Cognitive Impairment in Community-Dwelling Black Older Adults. <i>International Journal of Psychiatry in Medicine</i> , 2002, 32, 55-67.	0.8	4
118	Statins inhibit A β -neurotoxicity in vitro and A β -induced vasoconstriction and inflammation in rat aortae. <i>Atherosclerosis</i> , 2002, 161, 293-299.	0.4	32
119	Pro-inflammatory effect of freshly solubilized A β -amyloid peptides in the brain. <i>Prostaglandins and Other Lipid Mediators</i> , 2002, 70, 1-12.	1.0	41
120	CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker of Alzheimer's disease. <i>Journal of Neuroimmunology</i> , 2002, 132, 164-172.	1.1	52
121	Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. <i>Nature Neuroscience</i> , 2002, 5, 1288-1293.	7.1	196
122	Association between Alzheimer's Disease and a Functional Polymorphism in the Myeloperoxidase Gene. <i>Experimental Neurology</i> , 2001, 167, 456-459.	2.0	59
123	CD40 signaling and Alzheimer's disease pathogenesis. <i>Neurochemistry International</i> , 2001, 39, 371-380.	1.9	60
124	Characterization of murine immunoglobulin G antibodies against human amyloid- β 42. <i>Neuroscience Letters</i> , 2001, 307, 101-104.	1.0	73
125	Molecular genetics of Alzheimer's disease: the role of A β -amyloid and the presenilins. <i>Current Opinion in Neurology</i> , 2000, 13, 377-384.	1.8	75
126	Abeta Vasoactivity: An Inflammatory Reaction. <i>Annals of the New York Academy of Sciences</i> , 2000, 903, 97-109.	1.8	29

#	ARTICLE	IF	CITATIONS
127	beta-Amyloid Vasoactivity and Proinflammation in Microglia Can Be Blocked by cGMP-Elevating Agents. <i>Annals of the New York Academy of Sciences</i> , 2000, 903, 446-450.	1.8	24
128	Elevated A β 2 and Apolipoprotein E in A β 2PP Transgenic Mice and Its Relationship to Amyloid Accumulation in Alzheimer's Disease. <i>Molecular Medicine</i> , 2000, 6, 430-439.	1.9	73
129	CD45 Inhibits CD40L-induced Microglial Activation via Negative Regulation of the Src/p44/42 MAPK Pathway. <i>Journal of Biological Chemistry</i> , 2000, 275, 37224-37231.	1.6	82
130	Family History of Dementia and Current Depression in Nondemented Community-Dwelling Older Adults. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2000, 13, 65-71.	1.2	3
131	Cholesterol Modulates Vascular Reactivity to Endothelin-1 by Stimulating a Pro-inflammatory Pathway. <i>Biochemical and Biophysical Research Communications</i> , 2000, 274, 553-558.	1.0	22
132	Novel strategies for opposing murine microglial activation. <i>Neuroscience Letters</i> , 2000, 278, 5-8.	1.0	41
133	Soluble A β 2-amyloid peptides mediate vasoactivity via activation of a pro-inflammatory pathway. <i>Neurobiology of Aging</i> , 2000, 21, 183-197.	1.5	61
134	Vasoactivity of Amyloid A β 2 Peptides. , 2000, , 281-294.		0
135	Adaptation of the circular platform spatial memory task for mice: use in detecting cognitive impairment in the APPSW transgenic mouse model for Alzheimer's disease. <i>Journal of Neuroscience Methods</i> , 1999, 87, 87-95.	1.3	151
136	Activation of microglial cells by the CD40 pathway: relevance to multiple sclerosis. <i>Journal of Neuroimmunology</i> , 1999, 97, 77-85.	1.1	73
137	Intravascular infusions of soluble A β 2-amyloid compromise the blood-brain barrier, activate CNS glial cells and induce peripheral hemorrhage. <i>Brain Research</i> , 1999, 818, 105-117.	1.1	63
138	Association of a functional μ -opioid receptor allele (+118A) with alcohol dependency. <i>American Journal of Medical Genetics Part A</i> , 1999, 88, 458-461.	2.4	102
139	Alzheimers disease is not associated with the hypertension genetic risk factors PLA2 or G protein β 3, either independently or interactively with apolipoprotein e. <i>American Journal of Medical Genetics Part A</i> , 1999, 88, 465-468.	2.4	4
140	Factors associated with depressive symptoms in non-demented community-dwelling elderly. <i>International Journal of Geriatric Psychiatry</i> , 1999, 14, 331-337.	1.3	34
141	Microglial Activation Resulting from CD40-CD40L Interaction After A β -Amyloid Stimulation. <i>Science</i> , 1999, 286, 2352-2355.	6.0	340
142	Intravascular A β 2-amyloid infusion increases blood pressure: implications for a vasoactive role of A β 2-amyloid in the pathogenesis of Alzheimer's disease. <i>Neuroscience Letters</i> , 1999, 268, 17-20.	1.0	31
143	Progressive and gender-dependent cognitive impairment in the APPSW transgenic mouse model for Alzheimer's disease. <i>Behavioural Brain Research</i> , 1999, 103, 145-162.	1.2	197
144	Inhibition of Alzheimer's A β 2-Amyloid Induced Vasoactivity and Proinflammatory Response in Microglia by a cGMP-Dependent Mechanism. <i>Experimental Neurology</i> , 1999, 157, 211-221.	2.0	68

#	ARTICLE	IF	CITATIONS
145	Alzheimer's β -amyloid peptides induce inflammatory cascade in human vascular cells: the roles of cytokines and CD40. <i>Brain Research</i> , 1998, 807, 110-117.	1.1	109
146	Newly described form of X-linked arthrogyriposis maps to the long arm of the human X chromosome. , 1998, 78, 450-454.		18
147	The ϵ 491A/T apolipoprotein E promoter polymorphism association with Alzheimer's disease: independent risk and linkage disequilibrium with the known APOE polymorphism. <i>Neuroscience Letters</i> , 1998, 252, 95-98.	1.0	57
148	Isoform-specific vasoconstriction induced by Apolipoprotein E and modulation of this effect by Alzheimer's β -amyloid peptide. <i>Neuroscience Letters</i> , 1998, 256, 73-76.	1.0	39
149	Role of Peroxynitrite in the Vasoactive and Cytotoxic Effects of Alzheimer's β -Amyloid1 β 40Peptide. <i>Experimental Neurology</i> , 1998, 152, 116-122.	2.0	33
150	No association between the low density lipoprotein receptor-related protein (LRP) gene and late-onset Alzheimer's disease in a community-based sample. <i>Neuroscience Letters</i> , 1997, 233, 145-147.	1.0	47
151	Long-Term Venous A β 1-40Infusion in Rats Causes Lung Hemorrhage and Brain Perivascular Gliosis. <i>Annals of the New York Academy of Sciences</i> , 1997, 826, 440-446.	1.8	0
152	No interaction between the APOE and the alpha-1-antichymotrypsin genes on risk for Alzheimer's disease. , 1997, 74, 192-194.		17
153	No association between the intronic presenilin-1 polymorphism and Alzheimer's disease in clinic and population-based samples. , 1997, 74, 202-203.		29
154	No association between the very low density lipoprotein receptor gene and late-onset Alzheimer's disease nor interaction with the apolipoprotein E gene in population-based and clinic samples. <i>Genetic Epidemiology</i> , 1997, 14, 299-305.	0.6	23
155	Familial and Population-Based Studies of Apolipoprotein E and Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 1996, 802, 16-26.	1.8	28
156	Dopamine DRD2/Cys311 is not associated with chronic schizophrenia. , 1996, 67, 483-484.		22
157	β -Amyloid-mediated vasoactivity and vascular endothelial damage. <i>Nature</i> , 1996, 380, 168-171.	13.7	690
158	Clinical features of early onset, familial Alzheimer's disease linked to chromosome 14. <i>American Journal of Medical Genetics Part A</i> , 1995, 60, 44-52.	2.4	9
159	Occurrence of the Cys311 DRD2 variant in a pedigree multiply affected with panic disorder. <i>American Journal of Medical Genetics Part A</i> , 1995, 60, 332-334.	2.4	17
160	The molecular genetics of Alzheimer's disease. <i>Molecular Neurobiology</i> , 1994, 9, 15-22.	1.9	19
161	THE MOLECULAR GENETICS OF EARLY ONSET FAMILIAL ALZHEIMER'S DISEASE. , 1994, , .		0
162	Age of onset in familial early onset Alzheimer's disease correlates with genetic aetiology. <i>American Journal of Medical Genetics Part A</i> , 1993, 48, 129-130.	2.4	47

#	ARTICLE	IF	CITATIONS
163	Molecular pathology of Alzheimer's disease. <i>International Review of Psychiatry</i> , 1993, 5, 351-362.	1.4	7
164	Familial Alzheimer's disease with the amyloid precursor protein position 717 mutation and sporadic Alzheimer's disease have the same cytoskeletal pathology. <i>Neuroscience Letters</i> , 1992, 137, 221-224.	1.0	87
165	Evidence for Allelic Heterogeneity in Familial Early-Onset Alzheimer's Disease. <i>British Journal of Psychiatry</i> , 1991, 158, 471-474.	1.7	28
166	The role of genetic factors in the etiology of the affective disorders. <i>Behavior Genetics</i> , 1990, 20, 235-250.	1.4	3
167	Molecular genetic studies of manic-depression and schizophrenia. <i>Trends in Neurosciences</i> , 1990, 13, 29-31.	4.2	15
168	The Impact of Molecular Genetics on Our Understanding of the Psychoses. <i>British Journal of Psychiatry</i> , 1989, 154, 591-595.	1.7	16
169	Alcoholism and the 'New Genetics'. <i>Addiction</i> , 1989, 84, 1433-1440.	1.7	10